MapLight Therapeutics Inc MPLT

US Biotechnology

$13.02 ▼ -7.20% ($-1.01)

⬇️ Below Yest. Low 🔥 High Short Interest 🗓️ Earnings Next Week

Open $14.42

Prev Close $14.03

Day Range $13.00 – $14.99

52W Range $9.10 – $40.43

Market Cap $554.89M

Beta 1.49

EPS (TTM) $-2.60

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2025-10-27
Shares Out.	45,350,000
Website	maplightrx.com/ ↗
Phone	16508394360
Employees	133
Net Income	-$60.7M
Total Assets	$418.8M
Total Liabilities	$19.0M
Equity	$399.8M

About MapLight Therapeutics Inc

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

MapLight Therapeutics Inc is a publicly traded company under the ticker symbol MPLT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.